CN1300208A - 冰淇淋型药物制剂及其制备方法 - Google Patents
冰淇淋型药物制剂及其制备方法 Download PDFInfo
- Publication number
- CN1300208A CN1300208A CN00800535A CN00800535A CN1300208A CN 1300208 A CN1300208 A CN 1300208A CN 00800535 A CN00800535 A CN 00800535A CN 00800535 A CN00800535 A CN 00800535A CN 1300208 A CN1300208 A CN 1300208A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- weight
- type
- milk
- ice cream
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 13
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract description 45
- 235000013336 milk Nutrition 0.000 claims abstract description 21
- 239000008267 milk Substances 0.000 claims abstract description 21
- 210000004080 milk Anatomy 0.000 claims abstract description 21
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 20
- 102000002322 Egg Proteins Human genes 0.000 claims abstract description 17
- 108010000912 Egg Proteins Proteins 0.000 claims abstract description 17
- 244000299461 Theobroma cacao Species 0.000 claims abstract description 17
- 235000009470 Theobroma cacao Nutrition 0.000 claims abstract description 17
- 235000013345 egg yolk Nutrition 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 15
- 239000006071 cream Substances 0.000 claims abstract description 11
- 235000015243 ice cream Nutrition 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 238000009472 formulation Methods 0.000 claims abstract 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 46
- 238000002360 preparation method Methods 0.000 claims description 43
- 229960005489 paracetamol Drugs 0.000 claims description 24
- 229940088594 vitamin Drugs 0.000 claims description 23
- 229930003231 vitamin Natural products 0.000 claims description 23
- 235000013343 vitamin Nutrition 0.000 claims description 23
- 239000011782 vitamin Substances 0.000 claims description 23
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 229960003022 amoxicillin Drugs 0.000 claims description 17
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 17
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 17
- 235000000346 sugar Nutrition 0.000 claims description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 14
- 239000002221 antipyretic Substances 0.000 claims description 14
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 14
- 239000003242 anti bacterial agent Substances 0.000 claims description 12
- 230000001754 anti-pyretic effect Effects 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 12
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 11
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 11
- 229940042585 tocopherol acetate Drugs 0.000 claims description 11
- 235000014121 butter Nutrition 0.000 claims description 10
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 7
- 229930003268 Vitamin C Natural products 0.000 claims description 7
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 7
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 7
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 7
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 7
- 229960002477 riboflavin Drugs 0.000 claims description 7
- 235000019192 riboflavin Nutrition 0.000 claims description 7
- 239000002151 riboflavin Substances 0.000 claims description 7
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 claims description 7
- 235000019154 vitamin C Nutrition 0.000 claims description 7
- 239000011718 vitamin C Substances 0.000 claims description 7
- 230000003115 biocidal effect Effects 0.000 claims description 6
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 6
- RDPGEFVUMRTSBB-UHFFFAOYSA-N D-3 Natural products O1C(=O)C=CC2=C1C=C1OCOC1=C2OCC(O)C(C)(O)C RDPGEFVUMRTSBB-UHFFFAOYSA-N 0.000 claims description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- FNJSWIPFHMKRAT-UHFFFAOYSA-N Monomethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(O)=O FNJSWIPFHMKRAT-UHFFFAOYSA-N 0.000 claims description 4
- -1 0.2-10.0% by weight Substances 0.000 claims description 3
- 229960002104 cyanocobalamin Drugs 0.000 claims description 3
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 3
- 239000011666 cyanocobalamin Substances 0.000 claims description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- 229960000723 ampicillin Drugs 0.000 claims description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 2
- 239000010775 animal oil Substances 0.000 claims description 2
- 229940106164 cephalexin Drugs 0.000 claims description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 2
- 229960000991 ketoprofen Drugs 0.000 claims description 2
- 229960005287 lincomycin Drugs 0.000 claims description 2
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 claims description 2
- 229960003966 nicotinamide Drugs 0.000 claims description 2
- 235000005152 nicotinamide Nutrition 0.000 claims description 2
- 239000011570 nicotinamide Substances 0.000 claims description 2
- PXWLVJLKJGVOKE-UHFFFAOYSA-N propyphenazone Chemical compound O=C1C(C(C)C)=C(C)N(C)N1C1=CC=CC=C1 PXWLVJLKJGVOKE-UHFFFAOYSA-N 0.000 claims description 2
- 229960002189 propyphenazone Drugs 0.000 claims description 2
- 235000020183 skimmed milk Nutrition 0.000 claims description 2
- 235000013322 soy milk Nutrition 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 2
- 229940125716 antipyretic agent Drugs 0.000 claims 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 2
- 229960000342 retinol acetate Drugs 0.000 claims 2
- 235000019173 retinyl acetate Nutrition 0.000 claims 2
- 239000011770 retinyl acetate Substances 0.000 claims 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims 2
- 235000013162 Cocos nucifera Nutrition 0.000 claims 1
- 244000060011 Cocos nucifera Species 0.000 claims 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 claims 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 229940116364 hard fat Drugs 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 229940088710 antibiotic agent Drugs 0.000 description 10
- 239000003826 tablet Substances 0.000 description 9
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 5
- 229960004860 thiamine mononitrate Drugs 0.000 description 5
- 235000019191 thiamine mononitrate Nutrition 0.000 description 5
- 239000011748 thiamine mononitrate Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000014860 sensory perception of taste Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及柔软的冰淇淋型药物制剂及其制备方法。本发明的冰淇淋型药物制剂通过下列步骤制备:搅拌混合蛋黄、奶和可可直到可可完全溶解在所述混合物中;搅拌奶油使其化成浆并将其与所述混合物以体积比为9∶1至5∶5混合;将药物加入所述混合物中并搅拌混合;和将所得混合物装入冰淇淋机中并配制成药物制剂。由于本发明的柔软的冰淇淋型制剂比常规的制剂在口服使用中的服用优势和吸收效力的优点,可用作儿童和婴儿的改善的药物配方而替代锭剂。
Description
发明背景
发明领域
本发明涉及柔软的冰淇淋型药物制剂及其制备方法。
现有技术的描述
解热剂、抗菌素和维生素已传统地配制成片剂、胶囊、液体、注射液和喷雾剂的形式。然而,证明传统的剂量形式不能满足感官的需要,不能方便地给儿童服药。因此,特别注意选择剂量形式,尤其是在口腔中的味觉和口感的细心品味下选择口服药用制剂。
遗憾的是,许多药品和活性成分都有一种刺激性的或其它令人不舒服的味觉,粗糙的或石灰渣的感觉。随着近年来药品工业的发展,为改善口腔中的味觉和口感,已开发出相对易于给儿童用药的药物制剂如可咀嚼的片剂、果冻型片剂和粒剂等。尽管可以商购获得,但这些药物制剂对儿童的吸引力并不理想。在这些情况下,急需开发研究新型用于儿童的药物制剂。
本发明的概述
本发明人经过努力开发了一种冰淇淋型的药物制剂,该药物制剂可用于如解热剂、抗菌素和维生素的药物,并发现该药物制剂提供了优良的药物吸收,从而在易于口服用药和高的吸引力方面改善了患者的药物适应。
本发明的主要目的是提供一种冰淇淋型的药物制剂。
本发明的另一个目的是提供制备所述冰淇淋型药物制剂的方法。
本发明的另一个目的是提供解热剂、抗菌素和维生素的冰淇淋型药物制剂。
附图的简要描述
本发明的上述和其它目的和特征在下面的结合附图的描述中将变得明显,其中:
图1为血液中的扑热息痛的HPLC图;
图2为口服用药后,片剂和冰淇淋型扑热息痛在血液中的含量的曲线图。
本发明的详细描述
本发明的冰淇淋型药物制剂通过下列步骤制备:搅拌混合蛋黄和奶直到其完全混合;搅拌奶油使其化成浆并将其与所述混合物以体积比为9∶1至5∶5,优选8∶2至6∶4,最优选7∶3,混合;将药物以0.1-20重量%的比例加入所述混合物中并搅拌混合;和将所得混合物装入冰淇淋机中并在温度范围为0℃至-10℃配制成药物制剂。
在制备冰淇淋型药物制剂时,也可以根据患者的喜好向蛋黄和奶的混合物中加入糖和/或可可,并且可以用椰子硬脂肪代替蛋黄。此外,上述奶包括豆奶、加工过的脱脂奶(含有7.2%的脱脂奶粉)和普通奶。上述奶油包括可商购的乳液奶油和羧甲基纤维素溶液(CMC),所述乳液奶油可以通过动物/植物油的离心获得。尽管在下面的实施例中对解热剂、抗菌素和维生素的几种药物制剂进行了描述,但在所述制剂中并不特别限于这些药物。所述解热剂包括扑热息痛、阿司匹林、布洛芬、酮洛芬、异丙基-安替比林,优选扑热息痛和/或它们的混合物;所述抗菌素包括阿莫西林、氨苄西林、红霉素、林肯霉素和头孢氨苄,最优选阿莫西林;所述维生素包括醋酸维生素A、维生素D-3、醋酸维生素E、维生素C、硝酸硫胺、核黄素、盐酸吡哆辛、烟酰胺和氰钴胺。
本发明在下列实施例中进一步说明,这些实施例不用于限制本发明的保护范围。实施例1:含有扑热息痛的解热剂的冰淇淋型制剂的制备
实施例1-1
将糖、可可、蛋黄和奶以表1的重量比例称重并搅拌混合直到其完全溶解。然后,搅拌商购的乳液奶油直到其化成浆并将其与所述混合物混合。然后,将一种解热剂,扑热息痛加入所得混合物中并搅拌混合,将混合物装入冰淇淋机(Philips,HR2034)中并在0℃至-10℃获得冰淇淋型配方。
表1.含有扑热息痛的冰淇淋型制剂的组成
实施例1-2
成分 | 比例(重量%) |
奶 | 加至100.00 |
糖 | 18.00 |
可可 | 3.60 |
蛋黄 | 6.00 |
乳液奶油 | 30.00 |
扑热息痛 | 0.20 |
按照实施例1-1类似的方法制备冰淇淋型解热制剂,所不同的是使用下列表2的组成。
表2.含有扑热息痛的冰淇淋型制剂的组成
实施例1-3
成分 | 比例(重量%) |
奶 | 加至100.00 |
糖 | 18.00 |
可可 | 3.60 |
蛋黄 | 6.00 |
乳液奶油 | 30.00 |
扑热息痛 | 1.00 |
按照实施例1-1类似的方法制备冰淇淋型解热制剂,所不同的是使用下列表3的组成。
表3.含有扑热息痛的冰淇淋型制剂的组成
实施例2:含有阿莫西林抗菌素的冰淇淋型制剂的制备
成分 | 比例(重量%) |
奶 | 加至100.00 |
糖 | 18.00 |
可可 | 3.60 |
蛋黄 | 6.00 |
乳液奶油 | 30.00 |
扑热息痛 | 10.00 |
实施例2-1
按照实施例1-1类似的方法制备冰淇淋型抗菌素,所不同的是使用下列表4的组成。
表4.含有阿莫西林的冰淇淋型制剂的组成
实施例2-2
成分 | 比例(重量%) |
奶 | 加至100.00 |
糖 | 18.00 |
可可 | 3.60 |
蛋黄 | 6.00 |
乳液奶油 | 30.00 |
阿莫西林 | 0.20 |
按照实施例1-1类似的方法制备冰淇淋型抗菌素,所不同的是使用下列表5的组成。
表5.含有阿莫西林的冰淇淋型制剂的组成
实施例2-3
成分 | 比例(重量%) |
奶 | 加至100.00 |
糖 | 18.00 |
可可 | 3.60 |
蛋黄 | 6.00 |
乳液奶油 | 30.00 |
阿莫西林 | 1.00 |
按照实施例1-1类似的方法制备冰淇淋型抗菌素,所不同的是使用下列表6的组成。
表6.含有阿莫西林的冰淇淋型制剂的组成
实施例3:含有维生素的冰淇淋型制剂的制备
成分 | 比例(重量%) |
奶 | 加至100.00 |
糖 | 18.00 |
可可 | 3.60 |
蛋黄 | 6.00 |
乳液奶油 | 30.00 |
阿莫西林 | 10.00 |
实施例3-1
按照实施例1-1类似的方法制备冰淇淋型维生素制剂,所不同的是使用下列表7所列的醋酸维生素A、维生素D-3、醋酸维生素E、维生素C、硝酸硫胺、核黄素、盐酸吡哆辛、烟酰胺和氰钴胺的成分。
表7.含有维生素的冰淇淋型制剂的组成
实施例3-2
成分 | 比例(重量%) |
奶 | 加至100.00 |
糖 | 18.00 |
可可 | 3.60 |
蛋黄 | 6.00 |
乳液奶油 | 30.00 |
醋酸维生素A | 0.002 |
维生素D-3 | 0.0004 |
醋酸维生素E | 0.02 |
维生素C | 0.04 |
硝酸硫胺 | 0.0008 |
核黄素 | 0.0008 |
盐酸吡哆辛 | 0.0012 |
烟酰胺 | 0.008 |
氰钴胺 | 0.000004 |
按照实施例1-1类似的方法制备冰淇淋型维生素制剂,所不同的是使用下列表8所列的醋酸维生素A、维生素D-3、醋酸维生素E、维生素C、硝酸硫胺、核黄素、盐酸吡哆辛、烟酰胺和氰钴胺的成分。
表8.含有维生素的冰淇淋型制剂的组成
实施例4:药物在血液中的含量的测量
成分 | 比例(重量%) |
奶 | 加至100.00 |
糖 | 18.00 |
可可 | 3.60 |
蛋黄 | 6.00 |
乳液奶油 | 30.00 |
醋酸维生素A | 0.1 |
维生素D-3 | 0.02 |
醋酸维生素E | 1.0 |
维生素C | 2.0 |
硝酸硫胺 | 0.04 |
核黄素 | 0.04 |
盐酸吡哆辛 | 0.06 |
烟酰胺 | 0.4 |
氰钴胺 | 0.0002 |
为测量扑热息痛的血液含量,将雄性SD鼠在用醚处理后在股动脉处进行套管插入术。当该SD鼠苏醒过来时,以每只100毫克扑热息痛/千克体重等量口服商购的扑热息痛片剂和扑热息痛冰淇淋型制剂。在等间隔的时间内采集血样,并将其注射进如下操作条件的HPLC。扑热息痛在血液中的含量的HPLC的分析结果见图1。
HPLC分析的操作条件:
柱:μBondapak C18(Water美国);
淋洗液:乙腈:1%乙酸乙酯(1∶9,v/v),流速为1毫升/分钟;
检测器:UV分光光度计(λ=254纳米)。
实施例5:血液中扑热息痛含量的变化
在试验鼠(见图2)以100毫克/千克的量口服实施例2-2中制备的50克冰淇淋型制剂(含有500毫克扑热息痛)和商购的扑热息痛片剂(含有500毫克扑热息痛)后,血液中扑热息痛含量的变化通过实施例4中描述的方法监测。如图2所示,对于含有扑热息痛(o)的冰淇淋型制剂的C最大在20分钟处,而对于片剂形式(·)则在30分钟处,并且冰淇淋型制剂的药物的血液含量是片剂型制剂的3倍。实施例6:血液中阿莫西林含量的变化
在试验鼠(见图2)以10毫克/千克的量口服实施例2-2中制备的50克冰淇淋型制剂(含有500毫克阿莫西林)和商购的阿莫西林胶囊(含有500毫克阿莫西林)后,血液中醋酸维生素E含量的变化通过实施例4中描述的方法监测。
结果证明阿莫西林的冰淇淋型制剂和胶囊制剂显示类似的血液含量曲线。实施例7:血液中醋酸维生素E含量的变化
在试验鼠(见图2)以1毫克/千克的量口服实施例3-2中制备的50克冰淇淋型制剂(含有500毫克醋酸维生素E)和商购的醋酸维生素E片剂(含有500毫克醋酸维生素E)后,血液中阿莫西林含量的变化通过实施例4中描述的方法监测。
结果证明醋酸维生素E的冰淇淋型制剂和片剂型制剂都显示类似的血液含量曲线。急性毒性
实施例1,2和3中制备的解热剂、抗菌素和维生素的冰淇淋型制剂的急性毒性用5组雄性和雌性鼠研究。结果显示在以有效量地给药解热剂500次,抗菌素5000次和维生素50000次达到5克/千克/天时,没有致死的老鼠。
本发明的含有解热剂、抗菌素或维生素作为活性成分的冰淇淋型制剂可以按照常规的配制方法通过含有表面活性剂、赋形剂、着色剂、稳定剂、缓冲剂、悬浮液、等渗液、其它添加剂、有机或无机载体制成口服的形式。
所述冰淇淋型制剂可以以2-20毫克/千克(20千克为标准体重)的口服剂量给儿童服用,也可根据药物类型、药物治疗、疾病、患者年龄和药物治疗的延续时间而变化。
如上述清楚的描述和说明,本发明提供了一种冰淇淋型药物制剂及其制备方法。本发明制备的冰淇淋型药物制剂对儿童具有较高的药物顺从易于儿童服用和良好的吸收,因此可以替代锭剂。
本发明的优选的实施方式只用于说明的公开,本领域的技术人员将理解的是对本发明的各种修改、添加和替代不背离本发明的范围和精神,应该在本发明的保护范围内。
Claims (14)
1.一种冰淇淋型药物制剂。
2.权利要求1的冰淇淋型药物制剂,其中所述药物为解热剂、抗菌素或维生素。
3.权利要求2的冰淇淋型药物制剂,其中所述解热剂选自由扑热息痛、阿司匹林、布洛芬、酮洛芬、异丙基-安替比林所组成的组中。
4.权利要求2的冰淇淋型药物制剂,其中所述抗菌素选自由阿莫西林、氨苄西林、红霉素、林肯霉素和头孢氨苄所组成的组中。
5.权利要求2的冰淇淋型药物制剂,其中所述维生素选自由醋酸维生素A、维生素D-3、醋酸维生素E、维生素C、硝酸硫胺、核黄素、盐酸吡哆辛、烟酰胺、氰钴胺或它们的混合物所组成的组中。
6.制备冰淇淋型药物制剂的方法,该方法包括下列步骤:搅拌混合蛋黄和奶直到其完全混合;搅拌奶油并将其与所述混合物以体积比为9∶1至5∶5混合;将药物以0.1-20重量%的比例加入所述混合物中并搅拌混合;和将所得混合物装入冰淇淋机中并制成药物制剂。
7.权利要求6的方法,该方法还包括将糖和/或可可与蛋黄和奶的混合物混合的步骤。
8.权利要求6的方法,其中所述蛋黄用椰子硬脂肪代替。
9.权利要求6的方法,其中所述奶用豆奶或加工过的脱脂奶代替。
10.权利要求6的方法,其中所述奶油为羧甲基纤维素溶液(CMC)或通过动物/植物油的离心获得的乳液奶油。
11.权利要求6的方法,其中所述药物为解热剂、抗菌素或维生素。
12.用权利要求6的方法制备的含有解热剂的冰淇淋型制剂,该制剂含有各自为3.0-18.0重量%的糖、可可、蛋黄和奶油,0.2-10.0重量%的扑热息痛,和奶。
13.用权利要求6的方法制备的含有抗菌素的冰淇淋型制剂,该制剂含有各自为3.0-18.0重量%的糖、可可、蛋黄和奶油,0.2-10.0重量%的阿莫西林,和奶。
14.用权利要求6的方法制备的含有多种维生素的冰淇淋型制剂,该制剂含有各自为3.0-18.0重量%的糖、可可、蛋黄和奶油,0.002-0.1重量%的醋酸维生素A,0.0004-0.02重量%维生素D-3,0.02-1.0重量%醋酸维生素E,0.04-2.0重量%维生素C,0.0008-0.04重量%硝酸硫胺,0.0008-0.04重量%核黄素,0.0012-0.06重量%盐酸吡哆辛,0.008-0.4重量%烟酰胺,0.000004-0.0002重量%氰钴胺,和奶。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1999/12520 | 1999-04-09 | ||
KR1019990012520A KR20000065822A (ko) | 1999-04-09 | 1999-04-09 | 아이스크림타입의 의약용 제형 및 그의 제조방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1300208A true CN1300208A (zh) | 2001-06-20 |
Family
ID=19579240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN00800535A Pending CN1300208A (zh) | 1999-04-09 | 2000-04-07 | 冰淇淋型药物制剂及其制备方法 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1089709A4 (zh) |
JP (1) | JP2002541184A (zh) |
KR (1) | KR20000065822A (zh) |
CN (1) | CN1300208A (zh) |
AU (1) | AU4146500A (zh) |
WO (1) | WO2000061110A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100402030C (zh) * | 2006-01-05 | 2008-07-16 | 珠海联邦制药股份有限公司 | 一种含阿莫西林的药物组合物及其制备方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030049304A1 (en) * | 2001-08-29 | 2003-03-13 | Somani Jitendra Krishan | Quiescently frozen ice products |
US6896923B2 (en) | 2002-11-07 | 2005-05-24 | Good Humor-Breyers Ice Cream | Frozen confection |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1071017A (en) * | 1965-07-07 | 1967-06-07 | Georg Hipp | Process for producing biologically active compositions |
US4218482A (en) * | 1979-02-05 | 1980-08-19 | Detyzco, Inc. | Frozen, nutritious pet food |
US5290605A (en) * | 1989-06-29 | 1994-03-01 | Niva Shapira | Sun-exposure nutritional supporting composition |
GR1001437B (el) * | 1992-11-05 | 1993-12-30 | Aggelos Kontos | Ζαχαροπλαστικό σύστημα χορηγήσεως φαρμακολογικώς δραστικών ουσιών. |
WO1997006697A1 (en) * | 1995-08-21 | 1997-02-27 | Unilever N.V. | Antioxidant comprising food products |
BG61964B1 (bg) * | 1996-03-05 | 1998-11-30 | Георги Г. Попов | Диетичен сладолед с високо белтъчно съдържание |
GR1002668B (el) * | 1996-03-15 | 1997-04-14 | N | Μεθοδος προσθηκης στειρου αεριου αζωτου και φαρμακολογικως δραστικων ουσιων εις στερεο γιαουρτι. |
KR100291142B1 (ko) * | 1998-09-15 | 2001-07-12 | 박호군 | 네오헤스페리딘디하이드로칼콘을포함하는동맥경화증,고지혈증,간질환,고혈당증의예방및치료용조성물 |
-
1999
- 1999-04-09 KR KR1019990012520A patent/KR20000065822A/ko not_active Application Discontinuation
-
2000
- 2000-04-07 CN CN00800535A patent/CN1300208A/zh active Pending
- 2000-04-07 JP JP2000610443A patent/JP2002541184A/ja active Pending
- 2000-04-07 AU AU41465/00A patent/AU4146500A/en not_active Abandoned
- 2000-04-07 EP EP00921116A patent/EP1089709A4/en not_active Withdrawn
- 2000-04-07 WO PCT/KR2000/000321 patent/WO2000061110A1/en not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100402030C (zh) * | 2006-01-05 | 2008-07-16 | 珠海联邦制药股份有限公司 | 一种含阿莫西林的药物组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1089709A1 (en) | 2001-04-11 |
JP2002541184A (ja) | 2002-12-03 |
EP1089709A4 (en) | 2002-01-23 |
KR20000065822A (ko) | 2000-11-15 |
WO2000061110A1 (en) | 2000-10-19 |
AU4146500A (en) | 2000-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW420607B (en) | Rapamycin pharmaceutical compositions for oral administration | |
EP1105123B1 (en) | Pharmaceutical compositions containing lipase inhibitors and chitosan | |
EP0267702B1 (en) | Spray dried acetaminophen | |
EP0524308A1 (en) | Nutritional supplement containing vitamin e | |
US5114929A (en) | Pharmaceutical formulation | |
JPH09503495A (ja) | 高濃度アセトアミノフェン溶液含有ゼラチンカプセル | |
JP3480939B2 (ja) | アモキシシリンおよびクラブラン酸含有の組成物 | |
EP0412125B1 (en) | Pharmaceutical dosage form for the medication of fish | |
JP2002526379A (ja) | インシュリン活性を増強する組成物およびその方法 | |
CN1067580A (zh) | 乙酸孕甾酮配方 | |
BRPI0613321A2 (pt) | sistema de distribuição de droga para um pó bioativo, produto do chocolate que tem uma distribuição uniforme de um pó bioativo que compreende o sistema de distribuição de droga, método para a distribuição de pós bioativos , uso de um lipìdio, produto de cacau que tem uma distribuição uniforme de um pó bioativo, método para a manufatura de um produto de chocolate que compreende um pó bioativo, método para melhorar a biodisponibilidade de um pó bioativo lipofìlico, método para minimizar o nìvel de degradação de um pó bioativo,método para a incorporação de substáncias bioativas em produtos de cacau, produto de chocolate ao vinho, método pra intensificar a absorção de um polifenol no sangue de um ser humano e método para promover a saúde vascular de um ser humano | |
JP3073224B2 (ja) | 脳機能改善用食品又は医薬品組成物並びにその製造方法 | |
US4792449A (en) | Method for drug administration | |
EP0114277B1 (en) | Carnivore anthelmintics | |
PT99623A (pt) | Processo para a preparacao de composicoes farmaceuticas para administracao por via oral que contem ciclosporina como ingrediente activo | |
CN1307990C (zh) | 甘油三酸酯降低剂组合物 | |
US6251421B1 (en) | Pharmaceutical composition containing psyllium fiber and a lipase inhibitor | |
CN1300208A (zh) | 冰淇淋型药物制剂及其制备方法 | |
US4076804A (en) | Erythromycin therapy | |
US20050101605A1 (en) | Oral liquid formulations of methotrexate | |
TWI334783B (en) | Pharmaceutical composition for facilitating the reduction of blood-alcohol concentration after alcohol intake | |
EP0073006B1 (en) | Medicinal composition and method of making same | |
WO2001091730A1 (en) | Mineral supplement | |
CN1268342C (zh) | 药物组合物 | |
CN1063926C (zh) | 促钙吸收作用的林蛙卵组合物及其制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |